Patients with moderate- or high-risk ACS should receive an early, invasive approach that includes concomitant antithrombotic therapy, including aspirin and clopidogrel as well as unfractionated heparin or low-molecular-weightheparin (eg, dalteparin, enoxaparin, nadroparin), intravenous platelet glycoprotein IIb/IIIa complex blockers (eg, tirofiban, eptifibatide), and a beta-blocker. Early revascularization is the goal.
Low-risk patients with NSTEMI ACS should undergo further follow-up with biomarkers and clinical assessment. Intermediate-risk NSTEMI ACS patients should undergo further diagnostic assessment quickly to determine their appropriate risk category.
Learn more about approaches to treatment.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Yasmine S. Ali. Fast Five Quiz: Acute Coronary Syndrome - Medscape - May 17, 2023.